Skip to main content
. 2020 Mar 27;24(9):5363–5374. doi: 10.1111/jcmm.15192

Figure 3.

Figure 3

miR‐155‐3p knock‐down sensitizes resistant glioma cells to TMZ. A, Relative miR‐155‐3p level was analysed by real‐time PCR in A172/TR and U87/TR cells. B, Cell viability assay in A172/TR cells transfected with anti‐miR‐con or anti‐miR‐155‐3p and treated with increasing dose of TMZ. C, Cell viability assay in U87/TR cells transfected with anti‐miR‐con or anti‐miR‐155‐3p and treated with increasing dose of TMZ. D, Edu assay of U87/TR and A172/TR cells transfected with anti‐miR‐con or anti‐miR‐155‐3p and treated with 100 μmol/L TMZ for 48 h. E, Colony formation assay in A172/TR cells transfected with anti‐miR‐con or anti‐miR‐155‐3p and treated with increasing dose of TMZ. F, Colony formation assay in U87/TR cells transfected with anti‐miR‐con or anti‐miR‐155‐3p and treated with increasing dose of TMZ. G, Apoptosis was analysed by flow cytometry in A172/TR cells transfected with anti‐miR‐con or anti‐miR‐155‐3p and treated with 100 μmol/L TMZ after 48 h. H, Apoptosis was analysed by flow cytometry in U87/TR cells transfected with anti‐miR‐con or anti‐miR‐155‐3p and treated with 100 μmol/L TMZ after 48 h. I, Western blotting of indicated proteins in U87/TR cells transfected with anti‐miR‐con or anti‐miR‐155‐3p and treated with 100 μmol/L TMZ after 48 h. Results were expressed as means ± SD of 3 independent experiments. **P < .01